Trial reportCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2023
Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack.
Registry-linked trialOpen access · goldAbstract readRandomized Controlled TrialMulticenter Study
In one paragraph
Trial report in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04078737 (Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
- Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the European Society of Cardiology Working Group on Thrombosis.European heart journal. Cardiovascular pharmacotherapy · 2024Pooled it
- Effect of insulin resistance on ticagrelor-versus clopidogrel-based dual antiplatelet therapy for secondary prevention of stroke in carriers ofCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026Trial
- BMI and Deescalation From Ticagrelor to Clopidogrel in Patients With Acute Myocardial Infarction: A Post Hoc Analysis of the TALOS-AMI Trial.JAMA network open · 2025Trial
- Real-World Dual Antiplatelet Therapy Use Exceeds Randomized Trials Boundaries With Possible Safety Issues in Patients With Large Artery Atherosclerosis-Insights From the READAPT Study.European journal of neurology · 2025Observational
- Trend and burden of ischemic stroke attributable to high body mass index in China from 1990 to 2021, with projection to 2044.PloS one · 2025Article
- A clinical-radiomics combined model based on carotid atherosclerotic plaque for prediction of ischemic stroke.Frontiers in neurology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 4 countries.
Jia ZhangDepartment of Neurology (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang) and The China National Clinical Research Center for Neurological Diseases (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang), Beijing Tiantan Hospital and Department of Epidemiology and Health Statistics (Tian), School of Public Health, Capital Medical University; Beijing Municipal Key Laboratory of Clinical Epidemiology (Tian); Research Unit of Artificial Intelligence in Cerebrovascular Disease (Zhao), Chinese Academy of Medical Sciences; Beijing Institute of Brain Disorders (Zhao), Collaborative Innovation Center for Brain Disorders; Advanced Innovation Center for Human Brain Protection (Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Anxin WangDepartment of Neurology (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang) and The China National Clinical Research Center for Neurological Diseases (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang), Beijing Tiantan Hospital and Department of Epidemiology and Health Statistics (Tian), School of Public Health, Capital Medical University; Beijing Municipal Key Laboratory of Clinical Epidemiology (Tian); Research Unit of Artificial Intelligence in Cerebrovascular Disease (Zhao), Chinese Academy of Medical Sciences; Beijing Institute of Brain Disorders (Zhao), Collaborative Innovation Center for Brain Disorders; Advanced Innovation Center for Human Brain Protection (Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xue TianDepartment of Neurology (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang) and The China National Clinical Research Center for Neurological Diseases (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang), Beijing Tiantan Hospital and Department of Epidemiology and Health Statistics (Tian), School of Public Health, Capital Medical University; Beijing Municipal Key Laboratory of Clinical Epidemiology (Tian); Research Unit of Artificial Intelligence in Cerebrovascular Disease (Zhao), Chinese Academy of Medical Sciences; Beijing Institute of Brain Disorders (Zhao), Collaborative Innovation Center for Brain Disorders; Advanced Innovation Center for Human Brain Protection (Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xia MengDepartment of Neurology (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang) and The China National Clinical Research Center for Neurological Diseases (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang), Beijing Tiantan Hospital and Department of Epidemiology and Health Statistics (Tian), School of Public Health, Capital Medical University; Beijing Municipal Key Laboratory of Clinical Epidemiology (Tian); Research Unit of Artificial Intelligence in Cerebrovascular Disease (Zhao), Chinese Academy of Medical Sciences; Beijing Institute of Brain Disorders (Zhao), Collaborative Innovation Center for Brain Disorders; Advanced Innovation Center for Human Brain Protection (Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xuewei XieDepartment of Neurology (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang) and The China National Clinical Research Center for Neurological Diseases (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang), Beijing Tiantan Hospital and Department of Epidemiology and Health Statistics (Tian), School of Public Health, Capital Medical University; Beijing Municipal Key Laboratory of Clinical Epidemiology (Tian); Research Unit of Artificial Intelligence in Cerebrovascular Disease (Zhao), Chinese Academy of Medical Sciences; Beijing Institute of Brain Disorders (Zhao), Collaborative Innovation Center for Brain Disorders; Advanced Innovation Center for Human Brain Protection (Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Jing JingDepartment of Neurology (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang) and The China National Clinical Research Center for Neurological Diseases (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang), Beijing Tiantan Hospital and Department of Epidemiology and Health Statistics (Tian), School of Public Health, Capital Medical University; Beijing Municipal Key Laboratory of Clinical Epidemiology (Tian); Research Unit of Artificial Intelligence in Cerebrovascular Disease (Zhao), Chinese Academy of Medical Sciences; Beijing Institute of Brain Disorders (Zhao), Collaborative Innovation Center for Brain Disorders; Advanced Innovation Center for Human Brain Protection (Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Jinxi LinDepartment of Neurology (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang) and The China National Clinical Research Center for Neurological Diseases (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang), Beijing Tiantan Hospital and Department of Epidemiology and Health Statistics (Tian), School of Public Health, Capital Medical University; Beijing Municipal Key Laboratory of Clinical Epidemiology (Tian); Research Unit of Artificial Intelligence in Cerebrovascular Disease (Zhao), Chinese Academy of Medical Sciences; Beijing Institute of Brain Disorders (Zhao), Collaborative Innovation Center for Brain Disorders; Advanced Innovation Center for Human Brain Protection (Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yilong WangDepartment of Neurology (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang) and The China National Clinical Research Center for Neurological Diseases (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang), Beijing Tiantan Hospital and Department of Epidemiology and Health Statistics (Tian), School of Public Health, Capital Medical University; Beijing Municipal Key Laboratory of Clinical Epidemiology (Tian); Research Unit of Artificial Intelligence in Cerebrovascular Disease (Zhao), Chinese Academy of Medical Sciences; Beijing Institute of Brain Disorders (Zhao), Collaborative Innovation Center for Brain Disorders; Advanced Innovation Center for Human Brain Protection (Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Zixiao LiDepartment of Neurology (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang) and The China National Clinical Research Center for Neurological Diseases (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang), Beijing Tiantan Hospital and Department of Epidemiology and Health Statistics (Tian), School of Public Health, Capital Medical University; Beijing Municipal Key Laboratory of Clinical Epidemiology (Tian); Research Unit of Artificial Intelligence in Cerebrovascular Disease (Zhao), Chinese Academy of Medical Sciences; Beijing Institute of Brain Disorders (Zhao), Collaborative Innovation Center for Brain Disorders; Advanced Innovation Center for Human Brain Protection (Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Liping LiuDepartment of Neurology (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang) and The China National Clinical Research Center for Neurological Diseases (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang), Beijing Tiantan Hospital and Department of Epidemiology and Health Statistics (Tian), School of Public Health, Capital Medical University; Beijing Municipal Key Laboratory of Clinical Epidemiology (Tian); Research Unit of Artificial Intelligence in Cerebrovascular Disease (Zhao), Chinese Academy of Medical Sciences; Beijing Institute of Brain Disorders (Zhao), Collaborative Innovation Center for Brain Disorders; Advanced Innovation Center for Human Brain Protection (Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Hao LiDepartment of Neurology (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang) and The China National Clinical Research Center for Neurological Diseases (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang), Beijing Tiantan Hospital and Department of Epidemiology and Health Statistics (Tian), School of Public Health, Capital Medical University; Beijing Municipal Key Laboratory of Clinical Epidemiology (Tian); Research Unit of Artificial Intelligence in Cerebrovascular Disease (Zhao), Chinese Academy of Medical Sciences; Beijing Institute of Brain Disorders (Zhao), Collaborative Innovation Center for Brain Disorders; Advanced Innovation Center for Human Brain Protection (Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yong JiangDepartment of Neurology (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang) and The China National Clinical Research Center for Neurological Diseases (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang), Beijing Tiantan Hospital and Department of Epidemiology and Health Statistics (Tian), School of Public Health, Capital Medical University; Beijing Municipal Key Laboratory of Clinical Epidemiology (Tian); Research Unit of Artificial Intelligence in Cerebrovascular Disease (Zhao), Chinese Academy of Medical Sciences; Beijing Institute of Brain Disorders (Zhao), Collaborative Innovation Center for Brain Disorders; Advanced Innovation Center for Human Brain Protection (Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xingquan ZhaoDepartment of Neurology (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang) and The China National Clinical Research Center for Neurological Diseases (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang), Beijing Tiantan Hospital and Department of Epidemiology and Health Statistics (Tian), School of Public Health, Capital Medical University; Beijing Municipal Key Laboratory of Clinical Epidemiology (Tian); Research Unit of Artificial Intelligence in Cerebrovascular Disease (Zhao), Chinese Academy of Medical Sciences; Beijing Institute of Brain Disorders (Zhao), Collaborative Innovation Center for Brain Disorders; Advanced Innovation Center for Human Brain Protection (Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University, Beijing, China zxq@vip.163.com yongjunwang@ncrcnd.org.cn.
Yongjun WangDepartment of Neurology (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang) and The China National Clinical Research Center for Neurological Diseases (Zhang, A. Wang, Tian, Meng, Xie, Jing, Lin, Yilong Wang, Z. Li, Liu, H. Li, Jiang, Zhao, Yongjun Wang), Beijing Tiantan Hospital and Department of Epidemiology and Health Statistics (Tian), School of Public Health, Capital Medical University; Beijing Municipal Key Laboratory of Clinical Epidemiology (Tian); Research Unit of Artificial Intelligence in Cerebrovascular Disease (Zhao), Chinese Academy of Medical Sciences; Beijing Institute of Brain Disorders (Zhao), Collaborative Innovation Center for Brain Disorders; Advanced Innovation Center for Human Brain Protection (Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University, Beijing, China zxq@vip.163.com yongjunwang@ncrcnd.org.cn.
Beijing Tian Tan Hospital · CNAcademia Sinica · TWAcademy of Medical Sciences · GBChinese Academy of Medical Sciences & Peking Union Medical College · CNChinese Institute for Brain Research · CNCapital Medical University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBody mass index (BMI) may affect the response to platelet P2Y
methodsIn a multicentre, randomized, double-blind, placebo-controlled trial, conducted in China, we randomized patients with minor stroke or TIA who carried the
resultsAmong 6412 patients, 876 were classified as obese and 5536 were classified as nonobese. Compared with clopidogrel-ASA, ticagrelor-ASA was associated with a significantly lower rate of stroke within 90 days among patients with obesity (25 [5.4%] v. 47 [11.3%]; hazard ratio [HR] 0.51, 95% confidence interval [CI] 0.30-0.87), but not among those in the nonobese group (166 [6.0%] v. 196 [7.0%]; HR 0.84, 95% CI 0.69-1.04) The interaction of treatment and BMI group was significant (
interpretationIn this secondary analysis of a randomized controlled trial involving patients with minor ischemic stroke or TIA, compared with clopidogrel-ASA, patients with obesity received more clinical benefit from ticagrelor-ASA therapy than those without obesity.
trial registrationClinicaltrials.gov, no. NCT04078737.
Indexed as
Ischemic Attack, TransientIschemic StrokeStrokeAspirinBody Mass IndexClopidogrelDrug Therapy, CombinationHemorrhageHumansObesityPlatelet Aggregation InhibitorsTicagrelorTreatment OutcomeAspirinClopidogrelPlatelet Aggregation InhibitorsTicagrelor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT04078737ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.